Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1 -Mutated Acute Myeloid Leukemia: An ALFA Study

Blood (2022) 140 (Supplement 1): 6303–6305.

https://doi.org/10.1182/blood-2022-163348

Published: 2022

Journal Articles

Multiparametric Flow Cytometry Evaluation of CD200L/CD200R- LSC/NK Synapse Including Leukemia Stem Cell (LSC) Fraction As a Potential Therapeutic Target and Marker of NK Cell Exhaustion in Pediatric AML-Conect-AML French Collaborative Network

Adriana Plesa, Octavia Cadassou, Joris Gutrin, Marine Villard, Christophe Roumier, Meyling Cheok, Florent Dumezy, Claude Preudhomme, Hélène Lapillonne, Arnaud Petit, Guy Leverger, Carine Halfon-Domenech, Cecile Renard, Yves Bertrand, Charles Dumontet, Sebastien Viel, Veronique Maguer-Satta, Thierry Walzer

Blood (2021) 138 (Supplement 1): 2375.

https://doi.org/10.1182/blood-2021-154181

Published: 2021

Journal Articles

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

Blood (2020) 135 (8): 542–546.

https://doi.org/10.1182/blood.2019003471

Published: 2020

Includes: Supplemental data

Journal Articles

Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC)

Adriana Plesa, Christophe Roumier, PharmD, Florent Dumezy, PharmD, Delphine Manzoni, PharmD, Pierre Sujobert, MD PhD, Sandrine Hayette, Isabelle Tigaud, MD, Claude Preudhomme, Karine Celli-Lebras, CRA, Yves Bertrand, MD, Herve Dombret, Xavier Thomas, MD, Meyling Cheok, BSPharm, PhD

Blood (2018) 132 (Supplement 1): 4009.

https://doi.org/10.1182/blood-2018-99-119857

Published: 2018

Journal Articles

A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients

Stanley W.K. Ng, Schoof E Erwin, Amanda Mitchell, PhD, Mark D. Minden, MD PhD, Lars Bullinger, MD, Hartmut Döhner, MD, Hervé Dombret, Claude Preudhomme, Meyling Cheok, BSPharm, PhD, John E. Dick, PhD, Jean C.Y. Wang, MD PhD

Blood (2018) 132 (Supplement 1): 2765.

https://doi.org/10.1182/blood-2018-99-114275

Published: 2018

Journal Articles

Targeting Aberrant Expression of CD81 Impacts Cell Adhesion and Migration, Drug Resistance and Prognosis of Acute Myeloid Leukemia

Fanny Gonzales, Thomas Boyer, Pauline Peyrouze, Soizic Guihard, Christophe Roumier, Céline Berthon, MD PhD, Claude Preudhomme, PharmD, PhD, Meyling Cheok, BSPharm, PhD

Blood (2017) 130 (Supplement 1): 2675.

https://doi.org/10.1182/blood.V130.Suppl_1.2675.2675

Published: 2017

Journal Articles

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes

Virginie Chesnais, Marie-Laure Arcangeli, Caroline Delette, Alice Rousseau, Hélène Guermouche, Carine Lefevre, Sabrina Bondu, M’boyba Diop, Meyling Cheok, Nicolas Chapuis, Laurence Legros, Sophie Raynaud, Lise Willems, Didier Bouscary, Evelyne Lauret, Olivier A. Bernard, Olivier Kosmider, Françoise Pflumio, Michaela Fontenay

Blood (2017) 129 (4): 484–496.

https://doi.org/10.1182/blood-2016-03-707745

Published: 2017

Includes: Supplemental data

Journal Articles

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Blood (2014) 124 (21): 68.

https://doi.org/10.1182/blood.V124.21.68.68

Published: 2014

Journal Articles

Prognostic Analysis of GATA2 Mutations in CEBPA -Mutated Acute Myeloid Leukemia

Alice Marceau-Renaut, Meyling Cheok, Nicolas Duployez, Olivier Nibourel, Nathalie Helevaut, Céline Rodriguez, Karine Celli-Lebras, Céline Berthon, Guy Leverger, MD, Nicolas Boissel, MD PhD, Christine Terré, Xavier Thomas, Sylvie Castaigne, Herve Dombret, Claude Preudhomme, PharmD, PhD, Aline Renneville

Blood (2014) 124 (21): 2360.

https://doi.org/10.1182/blood.V124.21.2360.2360

Published: 2014

Journal Articles

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Blood (2014) 124 (21): 2324.

https://doi.org/10.1182/blood.V124.21.2324.2324

Published: 2014

Journal Articles

Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group

Blood (2014) 124 (21): 2327.

https://doi.org/10.1182/blood.V124.21.2327.2327

Published: 2014

Journal Articles

Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis

Blood (2014) 124 (21): 1007.

https://doi.org/10.1182/blood.V124.21.1007.1007

Published: 2014

Journal Articles

DEK and WT1 Affect Alternative Splicing of Genes Involved in Hematopoietic Cell Lineage and Resistance to Chemotherapy in Acute Myeloid Leukemia Cells.

Aminetou Mint Mohamed, Morgan Thenoz, Catherine Koering, Pierre Mallinjoud, Didier Auboeuf, Francoise Solly, Meyling Cheok, Olivier Nibourel, Claude Preudhomme, Eric Wattel, Franck Mortreux

Blood (2012) 120 (21): 2392.

https://doi.org/10.1182/blood.V120.21.2392.2392

Published: 2012

Journal Articles

SNP Array Analysis in Acute Myeloid Leukemia Reveals Frequent and Recurrent Acquired Genetic Alterations Linked to Prognosis: a Study of the ALFA Group

Olivier Nibourel, Christophe Roumier, Samuel Quentin, Sandrine Geffroy, Antonio Alberdi, Aline Renneville, Céline Berthon, MD, Celine Villenet, Martin Figeac, Herve Dombret, Jean Soulier, MD, Claude Preudhomme, Meyling Cheok

Blood (2011) 118 (21): 2533.

https://doi.org/10.1182/blood.V118.21.2533.2533

Published: 2011

Journal Articles

Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group

Blood (2010) 116 (21): 4171.

https://doi.org/10.1182/blood.V116.21.4171.4171

Published: 2010

Journal Articles

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission

Blood (2010) 116 (7): 1132–1135.

https://doi.org/10.1182/blood-2009-07-234484

Published: 2010

Includes: Supplemental data

Journal Articles

Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).

Blood (2009) 114 (22): 163.

https://doi.org/10.1182/blood.V114.22.163.163

Published: 2009

Journal Articles

Genome Wide SNP Analysis Reveals Frequent Cryptic Clonal Chromosomal Aberrations Including Uniparental Disomy (UPD) in Waldenstrom's Macroglobulinemia.

Stephanie Poulain, MD, Christophe Roumier, PhD, Meyling Cheok, PhD, Sylvie Zoutina, PhD, Agnes Daudignon, MPharm, Olivier Nibourel, MPharm, Valérie Soenen, MPharm, Jean Luc Lai, PhD, Jose Fernandez, MD, Claude Preudhomme, Patrick Duthilleul, MPharm, Pierre Morel, MD, Xavier Leleu

Blood (2009) 114 (22): 3932.

https://doi.org/10.1182/blood.V114.22.3932.3932

Published: 2009

Journal Articles

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)

Blood (2009) 114 (15): 3285–3291.

https://doi.org/10.1182/blood-2009-04-215814

Published: 2009

Includes: Supplemental data

Journal Articles

Inosine-Triphosphate-Pyrophosphatase Genotype Is a Determinant of Severe Fever with Neutropenia Following Treatment of Acute Lymphoblastic Leukemia with Combination Chemotherapy That Includes Mercaptopurine Adjusted for Thiopurine-S-Methyltransferase Genotype.

Gabriele Stocco, PhD, Meyling Cheok, PhD, Wenjian Yang, PhD, Thierry Dervieux, PharmD/PhD, Kristine Crews, PharmD, Deqing Pei, Cheng Cheng, PhD, Ching-Hon Pui, MD, Mary V. Relling, PharmD, William E. Evans, PharmD

Blood (2007) 110 (11): 2827.

https://doi.org/10.1182/blood.V110.11.2827.2827

Published: 2007

NARROW

LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1 -Mutated Acute Myeloid Leukemia: An ALFA Study

Multiparametric Flow Cytometry Evaluation of CD200L/CD200R- LSC/NK Synapse Including Leukemia Stem Cell (LSC) Fraction As a Potential Therapeutic Target and Marker of NK Cell Exhaustion in Pediatric AML-Conect-AML French Collaborative Network

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC)

A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients

Targeting Aberrant Expression of CD81 Impacts Cell Adhesion and Migration, Drug Resistance and Prognosis of Acute Myeloid Leukemia

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Prognostic Analysis of GATA2 Mutations in CEBPA -Mutated Acute Myeloid Leukemia

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group

Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis

DEK and WT1 Affect Alternative Splicing of Genes Involved in Hematopoietic Cell Lineage and Resistance to Chemotherapy in Acute Myeloid Leukemia Cells.

SNP Array Analysis in Acute Myeloid Leukemia Reveals Frequent and Recurrent Acquired Genetic Alterations Linked to Prognosis: a Study of the ALFA Group

Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission

Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).

Genome Wide SNP Analysis Reveals Frequent Cryptic Clonal Chromosomal Aberrations Including Uniparental Disomy (UPD) in Waldenstrom's Macroglobulinemia.

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)

Inosine-Triphosphate-Pyrophosphatase Genotype Is a Determinant of Severe Fever with Neutropenia Following Treatment of Acute Lymphoblastic Leukemia with Combination Chemotherapy That Includes Mercaptopurine Adjusted for Thiopurine-S-Methyltransferase Genotype.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only